Cargando…

Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy

AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionese, Michele, Basso, Umberto, Pierantoni, Francesco, Lai, Eleonora, Cavasin, Nicolò, Erbetta, Elisa, Jubran, Salim, Bonomi, Giorgio, Bimbatti, Davide, Maruzzo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/
https://www.ncbi.nlm.nih.gov/pubmed/37485441
http://dx.doi.org/10.2144/fsoa-2023-0049
_version_ 1785075487280726016
author Dionese, Michele
Basso, Umberto
Pierantoni, Francesco
Lai, Eleonora
Cavasin, Nicolò
Erbetta, Elisa
Jubran, Salim
Bonomi, Giorgio
Bimbatti, Davide
Maruzzo, Marco
author_facet Dionese, Michele
Basso, Umberto
Pierantoni, Francesco
Lai, Eleonora
Cavasin, Nicolò
Erbetta, Elisa
Jubran, Salim
Bonomi, Giorgio
Bimbatti, Davide
Maruzzo, Marco
author_sort Dionese, Michele
collection PubMed
description AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. RESULTS: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. CONCLUSION: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs.
format Online
Article
Text
id pubmed-10357407
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Future Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-103574072023-07-21 Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy Dionese, Michele Basso, Umberto Pierantoni, Francesco Lai, Eleonora Cavasin, Nicolò Erbetta, Elisa Jubran, Salim Bonomi, Giorgio Bimbatti, Davide Maruzzo, Marco Future Sci OA Research Article AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values. RESULTS: neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS. CONCLUSION: baseline inflammatory indexes are prognostic for mUC patients treated with ICIs. Future Science Ltd 2023-06-24 /pmc/articles/PMC10357407/ /pubmed/37485441 http://dx.doi.org/10.2144/fsoa-2023-0049 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Research Article
Dionese, Michele
Basso, Umberto
Pierantoni, Francesco
Lai, Eleonora
Cavasin, Nicolò
Erbetta, Elisa
Jubran, Salim
Bonomi, Giorgio
Bimbatti, Davide
Maruzzo, Marco
Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title_full Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title_fullStr Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title_full_unstemmed Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title_short Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
title_sort prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/
https://www.ncbi.nlm.nih.gov/pubmed/37485441
http://dx.doi.org/10.2144/fsoa-2023-0049
work_keys_str_mv AT dionesemichele prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT bassoumberto prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT pierantonifrancesco prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT laieleonora prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT cavasinnicolo prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT erbettaelisa prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT jubransalim prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT bonomigiorgio prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT bimbattidavide prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy
AT maruzzomarco prognosticroleofsystemicinflammationindexesinmetastaticurothelialcarcinomatreatedwithimmunotherapy